Sinopharm vaccine remained active vs South African variant, effect reduced
BEIJING — Two COVID-19 vaccines from Chinese companies including Sinopharm triggered immunity against a highly transmissible coronavirus variant first found in South Africa, but their effect appeared weaker, a small-sample lab study released on Tuesday showed.
Variants of the virus have stirred concern that they might weaken effects of vaccines and treatments developed prior to their emergence.
Twelve serum samples each taken from recipients of two vaccines developed by a subsidiary of China National Pharmaceutical Group (Sinopharm) and a unit of Chongqing Zhifei Biological Products retained neutralizing activity against the South African variant, their researchers said in a paper.
The paper was written by researchers from Sinopharm-affiliated Beijing Institute of Biological Products, the Institute of Microbiology of Chinese Academy of Sciences, which is co-developing a candidate with Zhifei unit, and two other Chinese agencies.
However, the samples’ activity against the variant was weaker than against the original virus and another variant currently spreading globally, according to the paper published on website BioRxiv ahead its peer-review.
Article continues after this advertisementThe activity reduction “should be taken into account for its impact for the clinical efficacy of these vaccines,” they said.
Article continues after this advertisementThe Sinopharm vaccine is approved in China for general public use and is also used in several other countries including the United Arab Emirates. The Zhifei shot is in late-stage clinical trials in China and overseas.
Preliminary clinical trial data on vaccines from Novavax Inc and Johnson & Johnson also showed they were significantly less effective at preventing COVID-19 in trial participants in South Africa, where the potent new variant is widespread.
EDV
For more news about the novel coronavirus click here.
What you need to know about Coronavirus.
For more information on COVID-19, call the DOH Hotline: (02) 86517800 local 1149/1150.
The Inquirer Foundation supports our healthcare frontliners and is still accepting cash donations to be deposited at Banco de Oro (BDO) current account #007960018860 or donate through PayMaya using this link.